Arabi, Yaseen M. http://orcid.org/0000-0001-5735-6241
Asiri, Ayed Y.
Assiri, Abdullah M.
Abdullah, Mashan L.
Aljami, Haya A.
Balkhy, Hanan H.
Al Jeraisy, Majed
Mandourah, Yasser
AlJohani, Sameera
Al Harbi, Shmeylan
Jokhdar, Hani A. Aziz
Deeb, Ahmad M.
Memish, Ziad A.
Jose, Jesna
Ghazal, Sameeh
Al Faraj, Sarah
Al Mekhlafi, Ghaleb A.
Sherbeeni, Nisreen Murad
Elzein, Fatehi Elnour
Hayden, Frederick G.
Fowler, Robert A.
AlMutairi, Badriah M.
Al-Dawood, Abdulaziz
Alharbi, Naif Khalaf
Funding for this research was provided by:
King Abdullah International Medical Research Center (RC15/142/R)
Article History
Received: 20 April 2022
Accepted: 19 October 2022
First Online: 28 October 2022
Competing interests
: YA is a Board Member of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). FGH is a nonpaid consultant on therapeutics for MERS-CoV and/or SARS-CoV-2 for Aphrodite/Daewoong, Appili, Arcturus, Atea, Cidara, Fujifilm, Gilead Sciences, GlaxoSmithKline, Merck, Pardes Biosciences, Pfizer, Primmune, Regeneron, Ridgeback, Roche/Genentech, SAB Biotherapeutics, Shin Poong Pharm, Takeda, and Vir. He served as member of a COVID-19 therapeutic trial DSMB for CytoDyn with payments to the University of Virginia. Other authors declared that they have no competing interests.